Blue Jet Healthcare's June quarter profit up by 141%, y-o-y

Mumbai, July 22, 2025 – Blue Jet Healthcare Ltd (NSE: BLUEJET | BSE: 544009)  reported a net profit of ₹911.70 million,  a 141% year-over-year increase. However,  there was a sharp fall in earnings on a sequential basis.

The share traded at ₹906.15 (10% down from the previous day’s close), hitting the lower circuit after the announcement of the results.

Financial Performance Trend Analysis

Blue Jet Healthcare delivered strong YoY growth, with revenue up 118% and net profit up 141%, driven by robust demand across product lines and effective cost optimisation. EBITDA margins also expanded significantly compared to Q1FY25. However, on a QoQ basis, while revenues grew modestly (+4%), profitability metrics like EBITDA and net profit declined ~15–17%, reflecting sequential pressure after a strong Q4FY25. The company’s annual growth trajectory remains healthy; however, sustaining margins in the upcoming quarters will be key.

Blue Jet Healthcare Stock Price Movement

Blue Jet Healthcare opened at ₹1,015 but hit its lower circuit of ₹906.15 (03:15 PM) down sharply on heavy volume (₹188 Cr traded), as investors reacted to a 17% QoQ profit decline despite strong YoY growth. The stock, which was near its 52-week high of ₹1,027.80, saw bearish sentiment take over, signalling caution in the near term.

Segmental and Operational Overview

While Blue Jet Healthcare does not report segment-wise revenue, the management reaffirmed that its strategic focus remains anchored on high-growth pharmaceutical intermediates. The inventory reduction contributed ₹750.07 million positively in Q1FY26, reversing last quarter’s buildup, signalling strong demand pull-through.

Taxation and EPS

Total tax expense stood at ₹316.90 million in Q1FY26, compared to ₹116.92 million in Q1FY25, reflecting the higher profit base. The earnings per share (EPS) stood at ₹5.26 per share (face value ₹2), versus ₹2.18 per share in the year-ago period.

Auditor’s Review

The unaudited financial results were reviewed by KKC & Associates LLP, which issued an unmodified conclusion, stating no material misstatements were found as per Regulation 33 of the SEBI (LODR) Regulations, 2015.

Board Meeting Timestamp

The Board meeting to approve the Q1FY26 results commenced at 11:58 AM and concluded at 12:25 PM on July 22, 2025.

Strategic Outlook

Blue Jet Healthcare continues to maintain a debt-light structure, with strong profitability and consistent demand in core therapeutic areas. With no subsidiaries or associates, the company’s performance reflects purely organic growth momentum. Management did not provide revenue guidance but hinted at sustained growth from APIs and contrast media intermediates.

Company Overview

Blue Jet Healthcare Ltd is a BSE and NSE-listed pharmaceutical intermediate and API manufacturer headquartered in Navi Mumbai. It specialises in artificial sweeteners, contrast media intermediates, and bulk drugs for the pharmaceutical and healthcare industries. The company has a consistent track record of profitability and operates a debt-light business model.

REF:https://nsearchives.nseindia.com/corporate/BLUEJET_22072025123549_Final_Upload_FS.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations